Navigation Links
Decoding dengue
Date:7/16/2014

Scientists have discovered a new pathway the dengue virus takes to suppress the human immune system. This new knowledge deepens our understanding of the virus and could contribute to the development of more effective therapeutics.

For years, the conventional approach to target the dengue virus was through vector control, which was regarded to be the most effective method. This is because the mechanics of the virus have been elusive, which in turn hampered the development of effective treatments and vaccines.

Fortunately a new study, published in the prestigious journal PLOS Pathogens, has given us fresh insight into the virus. Researchers from the Program in Emerging Infectious Diseases (EID) at Duke-NUS Graduate Medical School Singapore (Duke-NUS) have discovered a new way that dengue virus-2 (DENV-2) uses to evade the human defense system. Typically, when a virus enters the body and infects cells, it induces the production and release of interferons (IFNs), which are proteins that raise the bodies' anti-viral defense mechanisms.

The dengue virus enters the cell and produces large quantities of a non-coding, highly-structured viral RNA termed sfRNA, which is part of the genetic material of the dengue virus. The team found that sfRNA attaches itself to G3BP1, G3BP2 and CAPRIN1, proteins in the cell that typically help in producing antiviral proteins in response to IFNs. Because of this interaction, the cell is unable to mount its antiviral defenses and protect itself against virus replication.

"These findings were surprising because in 30 years of RNA and dengue related research this new mechanism was never discovered," explained senior author Professor Mariano Garcia-Blanco from EID.

"We not only found a new way in which the pathogen (dengue virus) interferes with the host response (human immune system) we also uncovered the first mechanistic insight into how this non-coding RNA works. This discovery opens the door to explore therapeutics through this channel."

These findings highlight new steps that regulate our immune response, and in the case of dengue, how the virus has learnt how to avoid these defenses. It also highlights the differences between the four dengue strains and how more research is needed to understand this highly complex virus.

"The dengue virus employs multiple strategies to evade our immune responses. These strategies provide the virus with redundancies so that if one approach fails, it has others to provide it with the necessary means to thrive," commented Associate Professor Eng Eong Ooi, Deputy Director of EID.

"Prof Garcia-Blanco's lab describes a novel way in which dengue virus is able to avoid being killed by our antiviral response. It produces fragments of its own genome to act like a sponge to soak up those factors needed to produce the virus killing machinery. This work is an important contribution to our overall understanding of the evasive strategies employed by dengue virus, which is important for devising new and effective methods for treating dengue patients."


'/>"/>

Contact: Dharshini Subbiah
dharshini.subbiah@duke-nus.edu.sg
659-616-7532
Duke-NUS Graduate Medical School Singapore
Source:Eurekalert

Related biology news :

1. Decoding worm lingo
2. Decoding the secrets of balance
3. Decoding the genome of the camel
4. Gene decoding obeys road traffic rules
5. Mathematical and biochemical design features for cell decoding of pulses revealed
6. Decoding characteristic food odors
7. Researchers identify Achilles heel of dengue virus, target for future vaccines
8. Spanish researchers design biomarkers for the detection of dengue and West Nile virus
9. Sanford-Burnham and 60° Pharmaceuticals to pursue promising target for the treatment of dengue fever
10. Research advances therapy to protect against dengue virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology: